Obsidian Therapeutics (OBX) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$1.19

Estimate

-$1.63

Surprise

+27.2%

Score at report (before → after)

4.8 → 4.4/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Obsidian Therapeutics (OBX) reported a narrower loss than forecast — diluted EPS of -$1.19 against the -$1.63 estimate (a 27.2% beat on a still-unprofitable quarter). TrendMatrix's engine moved from Data Issue (4.8/10) to Sell at 4.4/10 after the report — the engine's score fell despite the beat.

• Obsidian Therapeutics Files Prospectus Related To Resale Of Up To 29,164,045 Shares Of Common Stock By Selling Stockhold — benzinga, 2026-08-28

TrendMatrix currently rates OBX Sell at 4.6/10.

2 of the last 4 quarters beat the estimate; this quarter's +27.2% surprise compares with a +0.2% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$16.82

Price target

$36.12

Stop

$15.64

Upside to target

+114.7%

Reward-to-risk

7.7:1

Model outputs from TrendMatrix’s engine as of 2026-09-06 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.04B

P/E (fwd)

-7.9

52-week range

$14.57–$49.97

Off 52-week high

66.3%

RSI (14)

46

Volume vs avg

0.82×

Score today

4.6/10